Deuteroncology
Liege, BE · Founded 2022 · 101 employees on LinkedIn · 1 known investors
DeuterOncology is a clinical-stage biotech developing DO-2, a deuterated, brain-penetrant MET kinase and RAS pathway inhibitor for cancer patients, currently in a phase 1 clinical study. The molecule was in-licensed from OCTIMET Oncology and originally from Janssen Pharmaceutica.
Founders & leadership
Deuteroncology was founded in 2022 by Dr Timothy Perera and Timothy Perera.
DT
Dr Timothy Perera
TP
Timothy PererainFounder & CEO
Investors · 1
Frequently asked questions
- What does Deuteroncology do?
- DeuterOncology is a clinical-stage biotech developing DO-2, a deuterated, brain-penetrant MET kinase and RAS pathway inhibitor for cancer patients, currently in a phase 1 clinical study. The molecule was in-licensed from OCTIMET Oncology and originally from Janssen Pharmaceutica.
- Who founded Deuteroncology?
- Deuteroncology was founded by Dr Timothy Perera, Timothy Perera in 2022.
- Who are Deuteroncology's investors?
- Deuteroncology's investors include Newton Biocapital.
- Where is Deuteroncology headquartered?
- Deuteroncology is headquartered in Liege, BE.